|
|
| | YK-2-69 Basic information |
| Product Name: | YK-2-69 | | Synonyms: | YK-2-69;Methanone, [6-[[4-[2-(dimethylamino)-6-benzothiazolyl]-5-fluoro-2-pyrimidinyl]amino]-3-pyridinyl](4-ethyl-1-piperazinyl)- | | CAS: | 2619846-89-6 | | MF: | C25H27FN8OS | | MW: | 506.6 | | EINECS: | | | Product Categories: | | | Mol File: | 2619846-89-6.mol |  |
| | YK-2-69 Chemical Properties |
| Boiling point | 715.0±70.0 °C(Predicted) | | density | 1.357±0.06 g/cm3(Predicted) | | pka | 7.04±0.10(Predicted) | | form | Solid | | color | White to light yellow |
| | YK-2-69 Usage And Synthesis |
| Description | YK-2-69 is a highly selective DYRK2 inhibitor which specifically interacts with Lys-231 and Lys-234 in the co-crystal structure. Especially, YK-2-69 exhibits more potent anti-PCa efficacy than the first-line drug enzalutamide in vivo. | | Uses | YK-2-69 is a highly selective DYRK2 inhibitor with an IC50 value of 9nM. YK-2-69 specifically interacts with Lys-231 and Lys-234 of DYRK2 and can be utilized in researches related to prostate cancer[1]. | | IC 50 | DYRK2: 9 nM (IC50) | | References | [1] Yuan K, et al. Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer. Nat Commun. 2022 May 25;13(1):2903. DOI:10.1038/s41467-022-30581-4 |
| | YK-2-69 Preparation Products And Raw materials |
|